Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:33:22 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



Q:SAGE - SAGE THERAPEUTICS INC - http://www.sagerx.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SAGE - Q1.013.39·14.001.013.94+0.8356.4895.411,7769,16213.46  13.97  13.4559.99  10.9219:47:26Apr 2515 min RT 2¢

Recent Trades - Last 10 of 9162
Time ETExPriceChangeVolume
19:47:26Q13.710.605300
18:55:59Q13.940.83520
17:58:39Q13.800.69525
17:30:08Q13.81880.71381
17:30:08Q13.72120.61621
17:30:08Q13.820.7151
16:53:20Q13.460.3551
16:53:19Q13.460.3551
16:53:19Q13.460.3551
16:53:19Q13.460.3551

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-25 06:30U:SAGENews ReleaseSage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
2024-04-17 06:30U:SAGENews ReleaseSage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease
2024-04-11 06:30U:SAGENews ReleaseSage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
2024-02-28 06:30U:SAGENews ReleaseSage Therapeutics to Present at Upcoming March Investor Conferences
2024-02-14 06:30U:SAGENews ReleaseSage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
2024-01-31 06:30U:SAGENews ReleaseSage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
2024-01-02 06:30U:SAGENews ReleaseSage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
2023-12-14 06:30U:SAGENews ReleaseZURZUVAE ¢ „ ¢ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
2023-11-08 06:30U:SAGENews ReleaseSage Therapeutics to Present at Upcoming November Investor Conferences
2023-11-07 06:30U:SAGENews ReleaseSage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
2023-10-24 06:30U:SAGENews ReleaseSage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
2023-10-18 06:30U:SAGENews ReleaseSage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington ¢ € ™s Disease
2023-09-06 06:30U:SAGENews ReleaseSage Therapeutics to Present at Upcoming September Investor Conferences
2023-08-31 06:30U:SAGENews ReleaseSage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE ¢ „ ¢ Commercial Launch and Pipeline Advancement
2023-08-07 06:30U:SAGENews ReleaseSage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
2023-08-04 22:45U:SAGENews ReleaseSage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023
2023-08-04 22:42U:SAGENews ReleaseFDA Approves ZURZUVAE ¢ „ ¢ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
2023-06-05 06:30U:SAGENews ReleaseSage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference